Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.59 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.53 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.53 |
| ▸ | CPT1A | P50416 | 1/20 | 0.50 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174578 | 0.89 | GRM5 (0.56) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL166646 | 0.81 | CHRNB2 (0.50) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL164387 | 0.76 | PARP14 (0.60) | — | |
| SCHEMBL166687 | 0.76 | CPT2 (0.50) | GRM5CPT1ACPT1B | |
| SCHEMBL164419 | 0.76 | CPT2 (0.50) | GRM5CPT1ACPT1B | |
| SCHEMBL11740531 | 0.76 | GRM5 (0.71) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL17069015 | 0.76 | HCRTR1 (0.46) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL165920 | 0.76 | ROCK2 (0.48) | GRM5 | |
| SCHEMBL167401 | 0.75 | ROCK2 (0.46) | CPT1ACPT1B | |
| SCHEMBL165005 | 0.75 | SCD (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611441-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028563-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053200-A1 | BACE 2 INHIBITORS | BACE2, BACE1, PSEN2 | GRM5 3723/4885HCRTR1 2091/4885HCRTR2 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.